Results 251 to 260 of about 8,117 (271)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis

Clinical and Experimental Allergy, 2022
Dawei Luo, Ekaterina Khaleva, Graham Roberts   +2 more
exaly  

Asthma exacerbations on benralizumab are largely non‐eosinophilic

Allergy, 2020
Sophie M. Poznanski, Manali Mukherjee, Nan Zhao, Chynna Huang, Katherine Radford, Ali A. Ashkar, Parameswaran Nair   +6 more
openaire   +3 more sources

Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children

Pediatric Pulmonology, 2021
Daniel M. Hinds, Jessica L. Bloom, Jennifer C. Cooper, Cullen M. Dutmer, Csaba Galambos, Jason P. Weinman, Michael E. Wechsler, Deborah R. Liptzin   +7 more
openaire   +3 more sources

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

Frontiers in Pharmacology, 2021
Giulia Scioscia, Carla Maria Irene Quarato, Donato Lacedonia   +2 more
exaly  

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Ioana Agache, Claudio Rocha, Yang Song
exaly  

Erenumab-aooe, Benralizumab, and Tezacaftor/ivacaftor

Journal of the American Pharmacists Association, 2018
Justin George, Daniel A. Hussar
openaire   +3 more sources

Benralizumab

Drugs of the Future, 2014
openaire   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Ioana Agache, Cezmi A Akdis, Mübeccel Akdis   +2 more
exaly  

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

European Respiratory Journal, 2022
Rania Dagher, Alan M Copenhaver, Alison A Humbles   +2 more
exaly  

Long-term Effectiveness of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.

Journal of Allergy and Clinical Immunology: In Practice
A. Nanzer, Anne-Catherine Maynard-Paquette, V. Alam, L. Green, L. Thomson, Jodie Lam, M. Fernandes, C. Roxas, G. D'ancona, A. Hearn, Jessica Gates, Sangita Agarwal, Brian D. Kent, Michelle Fernando, David D’Cruz, Claire Hopkins, Tevfik F. Ismail, J. Dhariwal, David J. Jackson   +18 more
semanticscholar   +1 more source